Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the xanthine class of organic compounds. Xanthines are purine derivatives characterized by a ketone group conjugated at specific positions on the purine ring. The drug is identified in DrugBank as DB08743 and has been described primarily in experimental and research contexts. Its precise mechanism of action and clinical indications are not detailed in public sources; however, xanthines commonly act as phosphodiesterase inhibitors or adenosine receptor antagonists. No approved therapeutic use or marketed product based on this molecule has been identified[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-({8-[(3R)-3-aminopiperidin-1-yl]-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl}methyl)benzonitrile.